Pharma & Biotech
Will Next-Generation Weight-Loss Drugs Replace GLP-1s?
Don't just read what happened. See what could happen next.
Prediction
Next-gen combinations and orals expand the market more than they instantly replace incumbent injectable GLP-1s over the next 24 months.
- Confidence
- 49%
- Horizon
- 24–60 months
- Impact
- High
- Direction
- Increasing
Prediction changed +7 points in 21 days
Short answer
GLP-1s redefined obesity care. Past-year pipelines emphasize dual/triple agonists, amylin combos, and orals — likely complements and upgrades in waves, not a single overnight replacement.
Why this question matters
Replacement timing swings hundreds of billions in pharma value and reshapes compounding, coverage, and supply.
What's happening now?
Multi-agonist late-stage programs
Candidates aim for greater weight loss or better tolerability.
Signal · strong
Oral GLP-1 progress
Convenience could shift share without erasing injectables overnight.
Signal · strong
Incumbent franchise defense
Novo and Lilly expand indications, supply, and next labels.
Signal · strong
Payer management intensifies
Coverage rules may slow switching even when science advances.
Signal · moderate
What could happen next?
Scenario A
Gradual upgrade cycle
Patients migrate as new labels and supply allow.
Scenario B
Oral discontinuity
Convenient pills rapidly take new-start share.
Scenario C
Incumbents hold
Next-gen underdelivers; current GLP-1s remain standard.
Key companies / entities
- Novo Nordisk
- Eli Lilly
- Amgen
- Pfizer
- Roche
Evidence
- research
Obesity pipeline conference updates
- company
Company earnings obesity commentary
- news
Payer GLP-1 management news
Prediction history
- Sep 22, 202649%
- Sep 15, 202647%
- Sep 8, 202644%
- Sep 1, 202642%